Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GART | P22102 | 13/20 | 0.61 |
| ▸ | FOLR1 | P15328 | 3/20 | 0.58 |
| ▸ | ATIC | P31939 | 3/20 | 0.48 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.42 |
| ▸ | MTHFD1 | P11586 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6899022 | 1.00 | GART (0.61) | GARTFOLR1ATICSOSTMTHFD1 | |
| SCHEMBL6899009 | 1.00 | GART (0.61) | GARTFOLR1ATICSOSTMTHFD1 | |
| SCHEMBL7834566 | 0.95 | GART (0.55) | GARTFOLR1ATICSOSTMTHFD1 | |
| Pelitrexol SCHEMBL26910492 | 0.89 | GART (0.74) | GARTFOLR1ATICSOSTMTHFD1 | |
| Pelitrexol SCHEMBL13927981 | 0.89 | GART (0.74) | GARTFOLR1ATICSOSTMTHFD1 | |
| Pelitrexol SCHEMBL13916067 | 0.89 | GART (0.74) | GARTFOLR1ATICSOSTMTHFD1 | |
| SCHEMBL6900553 | 0.87 | GART (0.47) | GARTFOLR1ATIC | |
| SCHEMBL7145433 | 0.85 | GART (0.80) | GARTFOLR1ATICSOSTMTHFD1 | |
| SCHEMBL7745908 | 0.78 | GART (0.75) | GARTFOLR1ATIC | |
| Lometrexol SCHEMBL17520098 | 0.76 | GART (1.00) | GARTATICSOSTMTHFD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152753-A1 | Methods of use for novel sulfur containing organic nitrate compounds | NITROMED, INC. | 2004-08-05 | — | — | US | claimed |
| EP-1482977-A1 | COMBINATION THERAPIES FOR TREATING METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CELLS | PFIZER INC. (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040152753-A1 | Methods of use for novel sulfur containing organic nitrate compounds | NITROMED, INC. | 2004-08-05 | — | — | US | disclosed |
| US-20040043959-A1 | Combination therapies for treating methylthioadenosine phosphorylase deficient cells | AGOURON PHARMACEUTICALS INC. | 2004-03-04 | — | — | US | disclosed |
| WO-2003074083-A1 | COMBINATION THERAPIES FOR TREATING METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CELLS | PFIZER INC. (US) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152753-A1 | Methods of use for novel sulfur containing organic nitrate compounds | PTGS2, NOS2, PTGS1 | GART 3413/4885FOLR1 3817/4885ATIC 1542/4885 |
| US-20040043959-A1 | Combination therapies for treating methylthioadenosine phosphorylase deficient cells | APRT, MTAP, TYMP | GART 4/4885FOLR1 343/4885ATIC 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.